Inhibikase Therapeutics, Inc.
HealthcareNASDAQ:IKT · NASDAQ Capital Market
+$0.00 today
Vol 0.42M · Avg 1.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.9%
avg 9.7%
ROIC
-30.1%
avg 24.5%
ROA
-26.6%
avg -1588.7%
Analysis
ROA is currently the strongest return metric at -26.6% versus its period average of -1588.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark T. Iwicki | Chief Executive Officer & Director | $1.24M | — | 60 | $4.98M | 3.77% |
Christopher H. Cabell FACC | President, Head of Research & Development and Chief Medical Officer | $782,088.00 | — | 57 | $676,564.00 | 0.51% |
David John McIntyre | Chief Financial Officer | $668,292.00 | — | 56 | $986,319.00 | 0.75% |
John Adams | Chief Scientific Officer | — | — | — | — | — |
Chadwick J. Orevillo | Executive Vice President & Head of Development Operations | — | — | — | — | — |
Jeffrey J. Kagy | Chief Human Resources Officer | — | — | — | — | — |
Timothy J. Pigot | Chief Commercial & Strategy Officer | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$3.00M
Sells
0
$0.00
Net Sentiment
+$3.00M
Net buying
Most Active
Sands Capital Life Sciences Pulse Fund II, L.P.
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. Direct | Buy | 2.07M | $1.45 | $2,999,999.25 |
Analysis
Insiders reported 1 buys worth $3.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3.00M. Sands Capital Life Sciences Pulse Fund II, L.P. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -30.3% | +82.8% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -30.3% over three years. Forward estimates point to Revenue at +82.8% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$353.16M
Turn Therapeutics Inc.
NASDAQ:TTRX
$180.07M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Entera Bio Ltd.
NASDAQ:ENTX
$60.63M
eXoZymes, Inc.
NASDAQ:EXOZ
$60.20M
Estrella Immunopharma, Inc.
ESLA
$45.62M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages IKT?
Inhibikase Therapeutics, Inc. (IKT) lists 7 active executives. The top listed executive is John Adams, Chief Scientific Officer.
Are IKT insiders buying or selling?
Recent insider activity shows net buying of $69.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.